Asset Sale Sparks Surge: Q32 Bio's stock has exploded on X with chatter following the recent sale of its Phase 2 complement inhibitor, ADX-097, to Akebia Therapeutics. Posts on the platform highlight a dramatic price jump, with some noting a surge of over 150% in a single session. The deal is seen as a pivotal move, easing financial concerns and extending the company’s cash runway.
Mixed Reactions Emerge: While many on X express optimism about Q32 Bio’s strategic focus on other projects like bempikibart for alopecia areata, a few voices question the long-term value of the asset sale. Some discussions point to high trading volume as a sign of short-covering rallies, while others debate if the momentum can hold. The conversation remains dynamic as traders weigh in on potential entry and exit points.
Note: This discussion summary was generated from an AI condensation of post data.
Q32 Bio Insider Trading Activity
Q32 Bio insiders have traded $QTTB stock on the open market 3 times in the past 6 months. Of those trades, 0 have been purchases and 3 have been sales.
Here’s a breakdown of recent trading of $QTTB stock by insiders over the last 6 months:
- JODIE POPE MORRISON (CEO) sold 10,494 shares for an estimated $18,899
- LEE KALOWSKI (CFO and President) sold 4,240 shares for an estimated $7,636
- SHELIA M. VIOLETTE (Chief Scientific Officer) sold 2,990 shares for an estimated $5,384
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Q32 Bio Hedge Fund Activity
We have seen 17 institutional investors add shares of Q32 Bio stock to their portfolio, and 54 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MONACO ASSET MANAGEMENT SAM removed 280,800 shares (-47.4%) from their portfolio in Q3 2025, for an estimated $555,984
- BLACKROCK, INC. removed 85,672 shares (-47.9%) from their portfolio in Q3 2025, for an estimated $169,630
- GOLDMAN SACHS GROUP INC removed 63,539 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $125,807
- NUVEEN, LLC removed 55,886 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $83,270
- JANE STREET GROUP, LLC removed 46,635 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $92,337
- TWO SIGMA INVESTMENTS, LP added 31,506 shares (+inf%) to their portfolio in Q3 2025, for an estimated $62,381
- RENAISSANCE TECHNOLOGIES LLC removed 29,700 shares (-38.6%) from their portfolio in Q3 2025, for an estimated $58,806
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
